Amarin Corp Plc (AMRN)

[sharonc]

CTO appears specifically related to distribution agreements. I have not read through everything on this board from the last 24 hours so this may have been pointed out.

Amarin back on February 27th asked for confidential treatment of these two exhibits. One is the Canada distribution agreement and the other is the Middle East distribution agreement. I do not see how the timing of the SEC responding to Amarin's request for these arrangements is related to what is going on in the courts or at the FDA. These request to keep terms of agreements be kept confidential are pretty standard. The two actual exhibits, with the confidential terms omitted can be seen on the SEC website.

"Amarin Corporation plc submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on February 27, 2018.
Based on representations by Amarin Corporation plc that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:
Exhibit 10.67 through December 31, 2022
Exhibit 10.68 through December 31, 2022

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:
Brent J. Fields Secretary"